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Summary 
The hepatitis B virus (HBV) nucleocapsid antigen (HBcAg) was investigated as a carrier moiety 
for the immunodominant circumsporozoite (CS) protein repeat epitopes of Plasmodiumfakiparum 
and the rodent malaria agent P.  berghei.  For this purpose hybrid genes coding for [NANP]4 
(C75CS2) or [DP4NPN]2 (C75CS1) as internal inserts in HBcAg (between amino acids 75 and 
81) were constructed and expressed in recombinant Salmonella  typhimurium.  The resulting hybrid 
HBcAg-CS polypeptides purified from S.  typhimurium  were particulate and displayed CS and 
HBc antigenicity, however, the HBc antigenicity was reduced compared to native recombinant 
HBcAg.  Immunization of several mouse strains with HBcAg-CS1  and HBcAg-CS2 particles 
resulted in high titer, P. berghei- or P.fakiparum-specific  anti-CS antibodies representing all murine 
immunoglobulin G isotypes. The possible influence of carrier-specific immunosuppression was 
examined, and preexisting immunity to HBcAg did not significantly affect the immunogenicity 
of the CS  epitopes  within  HBcAg-CS1  particles.  Similarly,  the choice of adjuvant  did not 
significantly alter the immunogenicity of HBcAg-CS hybrid particles.  Immunization in complete 
or incomplete Freund's adjuvant or alum resulted in equivalent anti-HBc and anti-CS humoral 
responses. Examination of T cell recognition of HBcAg-CS particles revealed that HBcAg-specific 
T  cells were universally primed and CS-specific  T  cells were primed if the insert contained a 
CS-specific  T  cell recognition site. This indicates that the internal site in HBcAg is permissive 
for the inclusion of heterologous pathogen-specific T as well as B cell epitopes. Most importantly, 
90 and 100%  of BALB/c mice immunized with HBcAg-CS1 particles were protected against 
a P. berghei challenge infection in two independent experiments. Therefore, hybrid HBcAg-CS 
particles may represent a useful approach for future malaria vaccine development. 
T 
he ability to define peptidic B cell epitopes on protein 
antigens and characterize carbohydrate B cell epitopes 
has created interest in the potential use of these "haptenlike" 
antigens in vaccine development. However, peptide antigens 
as well as carbohydrate antigens often require conjugation 
to an immunogenic T  cell carrier moiety for efficient im- 
munogenicity. A number of observations suggest that the 
hepatitis B virus (HBV) 1 nucleocapsid antigen (HBcAg) may 
represent an efficient carrier moiety (for a review see refer- 
ence 1). The HBcAg is a particle composed of 180 subunits 
of a single 21.5-Kd polypeptide, and is highly immunogenic 
1 Abbreviations used in this paper: CS, circumsporozoite;  HBcAg, hepatitis 
B virus nucleocapsid  antigen; HBV, hepatitis B virus; TT, tetanus  toxoid. 
in humans as well as in experimental animal models (2). Studies 
in mice have provided insight into this enhanced immunoge- 
nicity. For example, HBcAg can directly activate B cells (i.e., 
T  cell independence) (3), as a protein antigen HBcAg also 
elicits  strong T  cell responses (4),  and HBcAg-specific Th 
cells can cooperate with envelope (HBsAg)-specific B cells 
to produce anti-HBs  (5).  Whereas there is a clear MHC- 
associated  hierarchy of anti-HBc  responsiveness,  no  non- 
responder strain has been identified among MHC disparate 
murine strains (4).  Furthermore, HBcAg can be expressed 
in Escherichia  coli and other prokaryotes and self-assembles 
into core particles. For these reasons, HBcAg has been em- 
ployed as a carrier moiety for chemically coupled or recom- 
binant, translationally fused peptide epitopes (6-14). Recently, 
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insertion of heterologous B cell epitopes without interfering 
with particle assembly (11). The inserted peptidic epitopes 
became surface accessible and highly immunogenic.  At the 
same time, incorporation of heterologous epitopes at the in- 
ternal position of HBcAg had the useful effect of reducing 
HBcAg-specific antigenicity and immunogenicity. In this re- 
port we have used recombinant HBcAg to present the Plas- 
modium berghei and P. falciparum dominant circumsporozoite 
(CS)  repeat  epitopes inserted  at  this internal  position. 
Immunization  with  irradiated  sporozoites  can  protect 
animals  and humans  against  malaria  (15-17).  This protec- 
tion is thought to be mediated by CTLs and CS-specific an- 
tibodies (18-26).  The dominant  B  cell epitopes of the CS 
antigens have been identified in repeat regions and synthetic 
or recombinant  peptides representing  these amino  acid se- 
quences have been prepared  as candidate vaccines (27-29). 
The level of protection against P. fakiparum challenge achieved 
in volunteers after immunization with a recombinant CS pro- 
tein or a synthetic peptide containing the CS repeat coupled 
to tetanus toxoid (TT) was disappointingly low (27, 28). The 
anti-CS antibody responses achieved in these studies were also 
correspondingly low,  and the toxicity of the carrier  made 
dose increases undesirable.  Therefore,  the ability of a high 
titer polyclonal anti-CS antibody response to protect against 
malaria infection remains unclear. The low immunogenicity 
of the TT-coupled synthetic peptides in human volunteers 
may have been linked to carrier-specific suppression of the 
antihapten  response in the face of preexisting anti-TT anti- 
bodies (28-30). Conceptually, preexisting high titer CS-specific 
antibodies may protect against infection, whereas, T cell-medi- 
ated protection against disease requires at least a limited de- 
gree of infection and presentation  of antigen.  Therefore, it 
would be desirable to elicit a protective antibody response 
in naive vaccinees,  possibly in combination with  adequate 
T  cell immunity. 
One  approach  that  succeeded in  eliciting  high  titer  CS 
repeat-specific antibodies,  which were protective in  an an- 
imal model, has been the synthesis of multiply branched CS- 
derived peptides or multiple antigen peptide systems (MAPs) 
(31). This prompted us to insert CS repeat epitopes into recom- 
binant hybrid HBcAg particles.  In this report, the B and T 
cell immunogenicity of such hybrid particles incorporating 
P. berghei and P. fakiparum CS repeat sequences was analyzed. 
Specific questions addressed included: (a) would HBcAg-CS1 
immunization induce protective immunity against challenge 
with P. berghei in mice; (b) are the HBcAg-CS particles im- 
munogenic in an adjuvant acceptable for human use; (c) what 
is the impact of preexisting high titer, anticarrier-specific an- 
tibodies on the immunogenicity of HBcAg-CS particles;  and 
(a  t) what is the source of T  cell helper function? If HBcAg 
is to be used as a carrier moiety for non-HBV vaccine devel- 
opment purposes, it may be desirable to include Th sites from 
the pathogen of interest (i.e., P..falciparum) for T cell memory 
recall. We therefore analyzed whether CS-specific Th cell rec- 
ognition sites as well as HBcAg-specific Th cell sites would 
be functionally active in HBcAg-CS hybrid particles. 
Materials  and Methods 
Mice.  Inbred murine strains were obtained from the breeding 
colony at the Scripps Research Institute.  Female mice 6-8 wk of 
age at the initiation of the experiments were used. For the malaria 
protection experiments, 6-wk-old female BALB/c mice (The Jackson 
Laboratory, Bar Harbor,  ME) were divided into 3 groups of 10 
and immunized  with 20 #g HBcAg-CS,.  20 #g of HBcAg, or 
PBS emulsified in CFA, and boosted with the same doses of an- 
tigen in IFA 2 wk later. The mice were challenged with P. berghei 
as described below 3 mo after the primary immunization. The pro- 
tection experiment  was performed twice in an identical fashion. 
Recombinant HBcAg and HBc-CS Hybrid Particles  and Synthetic Pep- 
tides.  Recombinant HBcAg subtype ayw was produced and purified 
as previously described (11). Two sets of synthetic oligonucleotides 
representing the coding sequences for the P. berghei and the P. j~l- 
ciparum CS repeat sequences, [DP4NPN]2 and [NANP]4, ligated 
into plasmid pNS14PS2 (32) were digested with Hpal and Xbal 
and transformed into the Salmonella typhimurium cya crp vaccine  strain 
x4064 (33). The oligonucleotide  sequences used were: [NANP]4 
I:5'-AAC  GCT AAC CCG AAT GCT AAC CCG AAC GCT 
AAC CCG AAC GCT AAC CCG-Y; [NANP]4 2:5'-CTA GAC 
GGG TTA GCG TTC GGG TTA GCG TTC GGG TTA GCA 
TTC GGG TTA GCG TTY; [DP4NPN]~ I:5'-GAC CCG CCG 
CCG CCG AAC CCG AAC GAC CCG CCG CCG CCG AAC 
CCG  AAC  T-Y; and  [DP4NPN]2 2:5'-CTA  GAG TTC  GGG 
TTC GGC GGC GGC GGG TCG TTC GGG TTC GGC GGC 
GGC GGG TC-Y. 
The resulting plasmids pC75CS1 and pC75CS2 (see Fig. 1) were 
analyzed by agarose electrophoresis, restriction analysis, and dideoxy 
DNA sequencing. Recombinant S. typhimurium were grown in Luria 
Bertani (LB) medium supplemented with 100 #g/ml ampicillin at 
37~  under  aeration and gentle  shaking (200 rpm).  Expression 
of the hybrid HBcAg-CS particles was confirmed by Western blot 
analysis (see Fig. 2). For immunoblotting,  cells from overnight cul- 
tures were taken up in 2 x  sample buffer and boiled for 10 min. 
Proteins were separated by 14% SDS-PAGE. The proteins were 
subsequently transferred to nitrocellulose, incubated with a P. J~l- 
ciparurn CS-specific mAb (pF2A10) (34), a rabbit  anti-P,  berghei 
sporozoite serum (kindly provided by Dr. Daniel Gordon, Walter 
Reed Army Institute  of Research), or a mAb recognizing  HBV 
pre-S2 (4408, courtesy of  Dr. Makoto Mayumi [Jichi Medical  School, 
Tochigi-Ken, Japan]) (35) and developed with peroxidase-coupled 
goat anti-mouse IgG (Medac, Hamburg, Germany) visualized on 
x-ray film (Kodak) after incubation with a chemiluminescent sub- 
strate (ECL; Amersham Corp.,  Arlington  Heights,  IL). Hybrid 
HBcAg-CS particles were purified from recombinant S. typhirnu- 
rium by hydroxylapatite and Sepharose 4B chromatography as pre- 
viously described for HBcAg from recombinant E. coli (11). Based 
on Edman degradation  and SDS gel electrophoresis, the hybrid 
HBcAg-CS particle preparations were at least 95% pure. Peptides 
derived from the dominant  repeat sequences of the CS proteins 
of P. berghei [DP4NPN]2 and P. fatcil)arum [NANP]4 were synthe- 
sized on an automated peptide synthesizer or by the simultaneous 
multiple peptide synthesis method (36), and were subjected  to HPLC 
on a C18 reverse phase column. The peptides used eluted as a single 
major peak (>90%). Synthetic peptides were produced at the Torrey 
Pines Molecular Biology Institute  (La Jolla, CA) and were gener- 
ously provided by Richard  Houghten. 
mA bs and Antibody Assays.  HBcAg-specific  mAb 3105 and 3120 
(37), and HBeAg-specific mAb 904 and 905 (38) were supplied 
by M. Mayumi. Polyclonal  rabbit anti-HBc/HBe was obtained com- 
mercially (Dako Corp., Carpinteria, CA). The recombinant HBcAg 
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wich ELISA.  mAbs coated on microtiter wells were used as the 
capture reagents followed by addition of varying concentrations 
of recombinant antigen. Polyclonal rabbit anti-HBc/HBe was used 
as the detecting antibody and peroxidase-labeled  goat anti-rabbit 
IgG as the probe. Anti-HBc and anti-peptide antibodies were mea- 
sured in pooled, murine sera by indirect solid-phase ELISA using 
HBcAg (50 rig/well) and CS-derived peptides (1.0/zg/well) as solid- 
phase  ligands  and goat anti-mouse IgG (or IgG isotype-specific 
antibodies)  as  second  antibody,  and  were  developed  with  a 
peroxidase-labeled  swine anti-goat IgG. The data are expressed as 
antibody titer representing the highest dilution of serum required 
to yield three times the  OD492 of preimmunization  sera.  Mice 
were immunized for determination of in vivo antibody production 
by intraperitoneal injection of HBcAg or HBcAg-CS hybrid parti- 
cles (10/zg) either emulsified in CFA or absorbed to alum for pri- 
mary immunization and in IFA for subsequent immunizations. 
Malaria Sporozoite  Production  and Antibody Assay.  Salivary gland 
sporozoites  used  to  measure  anti-CS-specific  antibody  in  im- 
munofluorescent antibody and ELISA assays were produced by 
feeding laboratory-reared Anopheles stephensi  mosquitoes on P. ber- 
ghei ANKA-infected mice or P. falciparum NF54-infected cell cul- 
tures. Midgut oocyst and salivary gland sporozoite infection rates 
were monitored and sporozoites from infected glands  were har- 
vested in  Medium  199  (Sigma  Chemical Co.,  St.  Louis,  MO), 
washed in a protein-free buffer (for ELISA use), counted using a 
hemacytometer, and frozen at  -70~  for use in ELISAs, or im- 
mediately transferred to multiwell (2,000-4,000 sporozoites/spot) 
printed slides, air dried at room temperature, and stored at - 20~ 
until used in immunofluorescent antibody assays. 
For ELISA, sporozoites were diluted in carbonate buffer, pH 
9.0, and 1,000  sporozoites were added per microtiter plate well, 
and anti-CS antibody was measured in pooled mouse sera by in- 
direct solid-phase ELISA as described above. The immunofluores- 
cent antibody assays were initiated by spreading 30/~1 of mouse 
serum diluted in Dulbecco's PBS, pH 7.4, into the slide well con- 
taining the dried sporozoites. The slide was incubated in a moist 
chamber at room temperature for 30 min, the well was aspirated 
dry and washed twice with 30/zl PBS followed by a 30-/zl aliquot 
of fluorescein-labeled anti-mouse IgG (H +  L) (Kirkegaard & Perry 
Laboratories, Inc., Gaithersburg, MD) (1:100 in PBS). After 30 rain, 
the well was washed as above before mounting in glycerol/PBS 
(10:1). Slides were examined under ultraviolet light at a magnification 
of 500 for fluorescence and graded from negative for no fluores- 
cence to 4+ for strong uniform fluorescence. The data are expressed 
as antibody titer representing the highest dilution of serum to yield 
at least  a 1+  fluorescence score. 
T Cell Proliferation  Assay.  Groups of mice were primed with 
either 10 #g of HBcAg or 50/~g of synthetic peptide in CFA by 
hind footpad injection. These amounts represented optimal immu- 
nization doses. 10 d after immunization, draining lymph node cells 
were harvested, pooled, and 5  x  105 cells in 0.1  ml of Click's 
medium were cultured with 0.1 ml of medium containing either 
HBcAg, various synthetic peptides,  or medium alone. Cells were 
cultured for 96 h at 37~  in a humidified 5% CO2 atmosphere, 
and during the final 16 h, 1/~Ci of [3H]thymidine (6.7 Ci/mmol; 
1 Ci =  37 GBq: New England Nuclear, Boston, MA) was added. 
The cells were then harvested onto filter strips for determination 
of [3H]thymidine incorporation. The data are expressed as counts 
per minute corrected for background proliferation in the absence 
ofAg (A cpm). The T cell nature of the proliferation was confirmed 
by analyzing nylon-wool column-enriched T cells in selected ex- 
periments.  All T cell activation experiments were performed at least 
twice, and representative experiments are depicted. 
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Malaria Challenge  Experiments.  A. stephensi  mosquitoes used to 
challenge immunized mice were infected with P. berghei ANKA 
by feeding on infected mice.  Mosquitoes used for this challenge 
had salivary gland sporozoite infection rates of 50-100% 18-22 d 
after the infectious blood meal. 
Mice were anesthetized by injection of P,  ompun/Ketamin/sterile 
water (3:15:48)  (0.1  ml/mouse)  (R.ompun,  100 mg/ml;  Mobay 
Corp.,  Shawnee,  KS;  Ketamine HCi,  100 mg/ml;  Fort Dodge 
Laboratories,  Fort Dodge, IA). Anesthetized mice were placed on 
a holding platform and the tails laid on top of a screened mosquito 
container. Mosquitoes were permitted to feed until blood was ob- 
served in the gut of five mosquitoes. Beginning 3 d after challenge, 
mice were checked daily for P. berghei  infection by microscopic ex- 
amination of Giemsa-stained  thin-smear tail bleeds. A minimum 
of 25 fields (x 400) were read before a mouse was determined nega- 
tive for infection. After two consecutive positive blood smears, mice 
were euthanized and serum collected.  Mice with negative blood 
smears were observed for a minimum of 11 and up to 25 d after 
challenge. 
Results and Discussion 
Antigenicity of Hybrid HBcAg-CS Particles.  The DNA se- 
quences coding for the immunodominant amino acid repeats 
in the CS proteins of P. berghei or P. falciparum were cloned 
into the vector pNS14PS2 at an internal site of the HBcAg 
gene (for the structure of the hybrid gene translation prod- 
ucts see Fig.  1). S. typhimurium cya crp vaccine strain x4064 
was transformed with the resulting DNA sequence-verified 
plasmids pC75CS1 and pC75CS2. The recombinant S. typhim- 
urium which contained the plasmids synthesized HBcAg fu- 
sion proteins displaying CS antigenicity by Western blot anal- 
ysis (Fig. 2). The purified hybrid HBcAg-CS particles were 
analyzed by electron microscopy (Fig. 3). Both hybrid HBcAg- 
CS1  and  HBcAg-CS2  proteins  were  able  to  form corelike 
particles. To investigate the antigenicity of the recombinant 
particles  they were compared to recombinant  HBcAg and 
HBeAg (a nonparticulate form of the HBV nucleocapsid) in 
a liquid-phase sandwich assay using mAbs specific for HBcAg 
and HBeAg, respectively, as solid-phase capture reagents (Table 
1). Insertion of either of the two CS repeat sequences studied 
Plasmodium falciparum CS 
HBc 1-75  (NANP)4  HBc 81-156  pre-S(2) 133-143 
......  ~^  ~  C75CS2 
Plasmodium berghei CS 
HBc 1-75  (DP  4 NPN) 2  HBc 81-156  pre-S(2) 133-143 
...........  ~  c75cs~ 
Figure  1.  Structure of hybrid HBcAg-CS proteins. Numbers indicate 
amino acid positions of native HBcAg and pre-S(2) (subtype ayw). (Right) 
Plasmid designations. The amino acid sequence of the CS repeat epitope 
inserts is indicated in the one-letter code. Figure 2.  Expression  of hybrid HBcAg-CS genes in S. typhimurium 
x4064 (pC75CS1) and x4064(pC75CS2),  x4064(pNS27-53PS2)  (32) ex- 
pressing a hybrid HBcAg/pre-S  gene is added for specificity  control and 
comparison of apparent molecular size. Proteins in whole bacterial cell 
lysates from overnight  cultures of x4064(pNS27-53PS2)  (lane 1), x4064 
(pC75CS1) (lane  2), and x4064(pC75CS2)  (lane  3) were separated  by 14% 
SDS-PAGE and stained with Coomassie  Brilliant  blue (left)  or transferred 
to nitrocellulose  and visualized by immunostaining with a monoclonal 
anti-pre-S(2) antibody (4408, kindly provided by m. Mayumi), with a 
monoclonal anti-P,  fatciparum CS repeat antibody (pF2A10), or a poly- 
clonal rabbit anti-P, berghei  CS serum (right). 
ablated recognition of hybrid HBcAg-CS particles by mAb 
3105. Lack of  recognition by mAb 3105 confirms our previous 
finding that HBcAg residues 75 to 81 are critically involved 
in  this  immunodominant  HBcAg  epitope  (11). Another 
confirmation-dependent HBcAg-specific epitope defined by 
mAb 3120 is partially preserved by insertions within amino 
acids 75 and 81. Hybrid HBcAg-CS particles are recognized 
by HBeAg-specific mAbs 904 and 905. Truncation of HBcAg 
beyond amino  acid position  149  exposes HBeAg epitopes 
without disrupting particle formation (39). Whether exposure 
of these HBeAg epitopes results from a conformational change 
within the particles or is predominantly due to liberation of 
HBeAg-like material from less stable truncated particles (40) 
is unclear. 
Immunogenicity  of HBcAg-CS Particles.  To determine the 
immunogenicity of the hybrid HBcAg-CS particles, five MHC 
Table  1.  Monoclonal  Analysis of HBcAg-C8  Hybrid Particles 
Monoclonal (OD492) 
Anti-HBc  Anti-HBe 
Antigen  Concentration  3105  3120  904  905 
~g/ml 
HBcAg  1.0  0.56  1.5  0.29  0.14 
0.2  0.30  1.1  0.14  0.04 
HBeAg  1.0  0.36  0.17  2.0  2.0 
0.2  0.19  0.03  2.0  2.0 
HBcAg-CS1  1.0  0.03  1.3  1.7  1.0 
0.2  0.02  0.45  1.4  0.86 
HBcAg-CS2  1.0  0.01  1.4  0.4  0.82 
0.2  0.01  0.4  0.16  0.65 
The indicated  recombinant  antigens were analyzed  in a liquid-phase sand- 
wich ELISA.  mAbs specific  for HBcAg  (mAbs 3105 and 3120) and HBeAg 
(mAbs 904 and 905) were used as solid-phase  capture reagents. Concen- 
trations (1.0 and 0.2/zg/ml) of recombinant antigens were added, and 
the second  antibody  was a rabbit polyclonal  antibody, which recognizes 
both HBcAg and HBeAg epitopes, and the assay was developed  with 
a peroxidase-labeled  goat anti-rabbit Ig. Data are expressed as OD492 
values corrected  for background. 
discordant mouse strains were immunized with HBcAg-CSt 
particles  and  three  mouse  strains  were  immunized  with 
HBcAg-CSz  particles.  The  HBcAg-CSt  particles  elicited 
high titer primary and secondary IgG serum antibodies reac- 
tive with the inserted P. berghei  CS repeat sequence in all strains 
tested. In fact, the anti-CS responses measured on synthetic 
[DP4NPN]2  were  significantly higher  than  the  anti-HBc 
titers  (Table  2).  The  anti-[DP4NPN]2  response correlated 
well with the anti-CS response (Table 2) and was not cross- 
reactive with the P. falciparum CS repeat sequence [NANP]4. 
Similarly,  immunization with HBcAg-CS2 particles elicited 
high titer anti-NANP4 IgG serum antibodies that correlated 
with the anti-CS response and were not crossreactive with 
Figure  3.  Electron  micrographs of HBcAg and HBcAg-CS hybrid  particles. (A) HBcAg; (B) HBcAg-CS1;  and (C) HBcAg-CS2. Particles  (100/~g/ml) 
were applied to grids and fixed  with 1.5% glutaraldehyde  plus 10% paraformaldehyde  in cacodylate  buffer, pH 7.4, for 10 min. The samples were 
then negatively stained with aqueous uranyl formate. 
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Antibody titer  (1/dilution) 
Strain  H-2  Time  HBcAg  CS  [DP4NPN]2  [NANP]4 
C57BL/10  b  10 d  2,560  0  10,240  0 
(B10)  24 d  10,240  640  163,840  0 
2  ~  655,360  163,840  >655,360  0 
B10.S  s  10 d  2,560  0  10,240  0 
24 d  2,560  640  163,840  0 
2  ~  163,840  163,840  >655,360  0 
B10.M  m  10 d  2,560  0  10,240  0 
24 d  2,560  640  40,960  0 
2  ~  40,960  10,240  163,840  0 
B10.BR  k  10 d  0  0  10,240  0 
24  d  2,560  640  163,840  0 
2  ~  40,960  10,240  655,360  0 
BALB/c  d  10 d  160  0  10,240  0 
24 d  2,560  640  40,960  0 
2  ~  163,840  40,960  >655,360  160 
Groups of three mice each of the indicated strains were immunized with 10 pg of hybrid HBcAg-CS1  particles in CFA and boosted with  10 #g 
in IFA. Sera were collected before immunization,  10 and 24 d after primary and 2 wk after secondary (2  ~  immunization. Sera were pooled and 
analyzed by solid-phase ELISA: HBcAg (50 ng/well); CS represents P. berghei  sporozoites (1,000/well); the P. berghei  repeat [DP4NPN]2  (1.0 #g/well) 
and the P. fatciparum repeat [NANP]4 (1.0/~g/well)  were the solid-phase ligands. 
Table  3.  Immunogenicity  of HBcAg-CS2 Particles in Mice 
Antibody titer  (1/dilution) 
Strain  Time  HBcAg  CS  [NANP]4  [DP4NPN]2 
C57BL/10  10 d  10,240  200  2,560  0 
(B10)  24 d  40,960  1,600  10,240  0 
2 ~  655,360  6,400  655,360  40 
B10.S  10 d  10,240  200  640  0 
24  d  40,960  400  1,280  0 
2  ~  >655,360  400  20,480  0 
BALB/c  10 d  10,240  0  0  0 
24 d  40,960  200  640  0 
2 ~  >655,360  1,600  40,960  0 
Groups of three mice each of the indicated strains were immunized with 10 pg of hybrid HBcAg-CS2 particles in CFA and boosted with 10 pg 
in IFA. Sera were collected before immunization, 10 and 24 d after primary and 2 wks after secondary (2  ~  immunization. Sera were pooled and 
analyzed by solid-phase ELISA: HBcAg (50 ng/well);  the P. fakiparum repeat [NANP]4 (1.0/~g/well);  and the P. berghei repeat [DP4NPN]2 (1.0 
~g/well)  were the solid-phase ligands. The anti-CS antibody titer was determined by immunofluorescent antibody assay. 
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Immunogen  Adjuvant  Time 
Antibody titer 0/dilution) 




CFA  2  163,840  0 
4  655,360  0 
IFA  2  163,840  0 
4  655,360  0 
Alum  2  163,840  0 
4  655,360  0 
CFA  2  2,560  10,240 
4  10,240  163,840 
IFA  2  10,240  2,560 
4  10,240  163,840 
Alum  2  10,240  10,240 
4  40,960  655,360 
Groups of three BALB/c mice were immunized with either HBcAg (10/~g) or hybrid HBcAg-CS1 particles (10 #g) prepared in three different 
adjuvants: CFA, IFA, or alum. Sera were collected  before  immunization and 2 and 4 wk after primary immunization. Sera were pooled and analyzed 
by solid-phase ELISA using HBcAg (50 ng/well) and [DP4NPN]2 (1.0 #g/well) as solid-phase ligands. 
the P. berghei repeat sequence (Table 3). Immunization with 
HBcAg-CS2 particles elicited more anti-HBc relative to an- 
tiinsert  antibodies  as  compared  with  immunization  with 
HBcAg-CSt particles.  The  reason for this disparity is un- 
known,  but  it  suggests  the potential  for insert  sequence- 
specific effects on particle assembly or stability.  Therefore, 
alternative  hybrid HBcAg-NANP constructs  are currently 
being examined in order to optimize  the immunogenicity 
of the NANP sequence.  The greatest anti-[NANP]4 response 
occurred in B10 (I-A  b) mice for which the inserted NANP 
sequence contains a Th as well as a B cell epitope (41, 42). 
In  a  separate experiment  we found  that  [NANP]4 within 
HBcAg-CS2 particles represents a functional T  cell site for 
B10 mice (see below). Therefore,  it appears that  [NANP]4 
may act as an additional  source of Th cell function in this 
particular strain.  The IgG subclasses elicited by immuniza- 
tion with hybrid HBcAg-CS1 particles were also examined. 
Similar  to  the distribution  of isotypes after immunization 
with native HBcAg (3), immunization of BALB/c mice with 
HBcAg-CSI particles elicited a primary anti-[DP4NPN]2 re- 
sponse comprised of all IgG isotypes. The IgG1, IgG2a, IgG2b, 
and IgG3 anti-[DP4NPN]2 titers were at least  1:40,960  24 d 
after immunization  with a single HBcAg-CS1 particle dose 
(data not shown). This demonstrates that HBcAg is capable 
of eliciting a broad IgG isotype response specific for the in- 
serted epitope, and will be a useful carrier moiety regardless 
of which isotype is desired. 
Effect of Adjuvant on Immunogenicity.  For vaccine purposes, 
a vaccine carrier moiety must be immunogenic  in an adju- 
vant suitable for human use. The only currently licensed ad- 
juvant for use in humans is alum.  We therefore investigated 
whether the enhanced immunogenicity of the carried CS epi- 
tope  in  hybrid  HBcAg-CS1  particles  would be preserved 
when employing alum as an adjuvant. To address this ques- 
tion we immunized  BALB/c  mice with  either  HBcAg or 
HBcAg-CS1 particles formulated with CFA, IFA, or alum, 
and  analyzed  the  primary  serum  anti-HBc  and  anti- 
[DP4NPN]2 IgG responses (Table 4). The primary anti-HBc 
and  anti-[DP4NPN]2  IgG  responses  were nearly  identical 
regardless of the adjuvants employed. The data demonstrate 
that  HBcAg can be used as a vaccine carrier  moiety with 
alum, an adjuvant acceptable for human use. A direct com- 
parison of anti-HBc responses after immunization in all three 
adjuvants with native recombinant HBcAg or HBcAg-CSt 
particles also illustrates the reduced anti-HBc response (i.e., 
"~16-fold)  after  immunization  with  hybrid  particles  with 
an internal  deletion at HBcAg position 75 to 81 (Table 4). 
Further characterization  and deletion of the residual native 
HBcAg epitope(s)  may  make  it  possible to  create  hybrid 
HBcAg particles without any native HBcAg antigenicity at 
the  B  cell  level.  This  would eliminate  anticarrier-specific 
antibody production, and would not diminish the diagnostic 
value of anti-HBc antibody as a marker  of past or present 
HBV infection. 
Effects of Preexisting Carrier-specific Immunity.  Preexisting 
immunity to a carrier protein may negatively affect the pro- 
tein's  ability to efficiently present  new haptens  (30).  This 
presents a potential problem when identical carrier moieties 
are used for several different haptens  as exemplified by the 
increasing use of conjugated oligosaccharide vaccines. Simi- 
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Figure  4.  Effects  of carrier-specific sup- 
pression on the anti-[DP4NPN]2 response 
after HBcAg-CS1 immunization. Groups 
of three BALB/c mice were primed with 
either CFA only (O-O), or t0 ~g of the 
following  antigens  in  CFA: HBcAg 
(@-@); a heterologous HBcAg-PSt  hybrid 
particle (El-IS]); or a truncated HBcAg 
monomer. P16 (D-I)  (first arrow). I me 
after priming, all groups were immunized 
with the HBcAg-CSt hybrid (10/zg; IFA) 
(second  arrow). A second  HBcAg-CS1  injec- 
tion (10/~g; IFA)  was given I me later (third 
arrow). Sera were collected  before  immuni- 
zation, 1 me after the primary injection 
(lO), 10 d (2~  and 24 d (2~  after 
the second  injection, and 2 wk (3~  and 
6 wk (3~  after the third injection. Sera were pooled and analyzed by solid-phase ELISA: HBcAg (50 ng/well) and the P. berghei  repeat [DP4NPN]2 
(1.0/~g/well) were used as solid-phase ligands. Antibody titers are expressed as the reciprocal of the highest dilution of sera to yield three times the 
0D492 reading of preimmunization sera. 
larly,  the use of TT or diphtheria  toxin as carrier moieties 
may be affected by the high level of preexisting immunity 
to these childhood vaccine components.  Anti-HBc from a 
preceding HBV infection or vaccination could theoretically 
limit  the usefulness of HBcAg as a vaccine carrier moiety. 
We therefore analyzed the impact of prior immunization with 
native recombinant HBcAg on the antihapten responses ob- 
tained after immunization  with  HBcAg-CSI particles.  For 
this purpose, BALB/c mice were primed with HBcAg or an- 
other HBcAg hybrid particle with an HBV envelope internal 
insert (HBcAg-PS  0 in CFA followed by two injections with 
HBcAg-CSi particles 1 and 2 me later (Fig. 4). As a nega- 
tive control, one group of mice was primed with CFA only. 
As a control for the effects of Th cell priming, another group 
was immunized with a structural  polypeptide of truncated 
HBcAg (P16) which primes HBcAg-specific Th but not B 
cells due to the absence of the conformation-dependent  B 
cell epitopes.  Mice primed with HBcAg demonstrated  the 
highest  anti-HBc responses at  all  time points,  as expected 
(Fig. 4 A). Note that priming with the heterologous HBcAg 
hybrid particle (HBcAg-PS1) elicited  significantly lower anti- 
HBc levels at the primary bleed (1  ~  and thereafter,  as com- 
pared to wild-type HBcAg, due to the deletion of HBcAg 
residues 75 to 81. Priming with the truncated structural poly- 
peptide (P16)  of HBcAg elicited little anti-HBc before the 
first injection with HBcAg-CSt (Fig.  4 A).  These varying 
levels of anti-HBc antibodies appeared to have little effect on 
anti-[DP4NPN]2 antibody production 10 d after the first in- 
jection with HBcAg-CSt partides (2~  (Fig. 4 B). How- 
ever, 24 d after the first injection (2~  the HBcAg-primed 
group  possessed the lowest  anti-[DP4NPN]2  titer  and  the 
highest  anti-HBc  titer  suggesting  some degree of carrier- 
specific suppression. However, 2 wk after the second HBcAg- 
CS1 injection (3~  no evidence of carrier-specific sup- 
pression existed, and extremely high titer anti-[DP4NPN]2 
antibody (6.7  x  108) was produced by the HBcAg-primed 
group (Fig. 4 B). The other groups atso demonstrated very 
high  titer  anti-[DP4NPN]2  responses  (1.04  x  107-1.7  x 
108) at this time point.  To our knowledge, serum antipep- 
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tide levels of this magnitude have not been previously reported. 
It is noteworthy that the [DP4NPN]2 peptide emulsified in 
CFA is nonimmunogenic  in the BALB/c strain used in this 
experiment  (data not shown; 43). Therefore, the enhanced 
antibody production to the peptidic [DP4NPN]2 epitope is 
due to HBcAg-specific carrier effects. 6 wk after the second 
injection with HBcAg-CSt particles (3~  the anti-HBc 
and anti-[DP4NPN]2 titers began to decline relative to the 
peak responses 2 wk after the last injection with the excep- 
tion of the anti-[DP4NPN]2 response of the unprimed group 
which was still rising  at the (3~  time point  (Fig.  4). 
In general, these data indicate that hybrid HBcAg particles 
are extremely effective as vaccine carrier moieties even in the 
presence of preexisting immunity to HBcAg. This suggests 
that HBcAg may be used repeatedly as a vaccine carrier for 
multiple  haptens. 
T Cell Immunogenicity.  It is clear from the preceding results 
that immunization with HBcAg-CS hybrid particles can elicit 
high titer serum antibodies specific for the CS repeat sequences. 
The source of T  cell help for anti-CS antibody production 
is an important  additional issue,  especially in terms of non- 
HBV vaccine development. Will it be possible to insert func- 
tional pathogen-specific Th cell recognition sites  as well as 
B cell epitopes into HBcAg? IfTh cells exclusively recognize 
the HBcAg carrier moiety, a potential T cell site derived from 
the pathogen  and included in an inserted  sequence would 
not  be functional.  Previously it  has been reported  that  a 
heterologous  NHz-terminally  fused  Th  cell  site  was  not 
functional (11), and a COOH-terminally  fused Th cell site 
was functional (14) in the context of HBcAg hybrid parti- 
cles.  It was therefore of interest  to examine the  specificity 
of T  cell recognition of HBcAg-CS hybrid particles.  Three 
H-2 congenic murine strains were immunized with HBcAg- 
CS1  and  the  corresponding  synthetic  CS repeat  sequence 
[DP4NPN]2, and T  cell proliferative  responses were analyzed 
after in vitro restimulation with HBcAg and the synthetic 
peptide (Table 5). Immunization  in all three H-2 congenic 
strains with HBcAg-CS1 particles primed HBcAg- but not 
[DP4NPN]2-specific  T  cells.  Immunization  with  the  CS1 Table  5.  T  Cell Recognition of HBcAg-CS Hybrid Particles 
Antigens ([3H]TdR Uptake,  A  cpm) 
HBcAg  [DP4NPN]2  [NANP]4  HBcAg-CS1  or 2 
Strain  H-2  Immunogen  (1.0 lg/ml)  (100/zg/ml)  (1.0/~g/ml)  (1.0/~g/ml) 
B10  b  HBcAg-CS1  30,917  1,050  -  78,250 
[DPgNPN]2  1,003  1,188  -  0 
B10.S  s  HBcAg-CS1  45,213  0  -  51,667 
[DP4NPN]2  2,509  407  -  0 
B10.P  p  HBcAg-CS1  24,348  0  -  55,352 
[DP4NPN]2  1,394  156  --  0 
B10  b  HBcAg-CS2  50,646  11,759  ~  43,995 
[NANP]4  6,968  0  74,637 
BALB/c  d  HBcAg-CS2  100,552  0  0  120,187 
[NANP]4  8,845  0  0  0 
Groups of three mice of the indicated strains were immunized  with 10 #g of the HBcAg hybrid particles (HBcAg-CS1 or HBcAg-CS2) or 50 #g 
of the P. berghei repeat peptide [DP4NPN]2 or 50 #g of the P. fakiparum repeat peptide [NANP]4. Draining lymph  node cells were collected, pooled, 
and cultured with the indicated  antigens, and T cell proliferation  was measured as [3H]TdR uptake corrected for background proliferation  in the 
absence of antigen (A cpm). 
Table  6.  Protection Against P.  berghei Challenge Infection 
Infected/noninfected  (Percent protection) 
Immunogen  Exp.  1  Exp.  2 
PBS  8/9 (11%)  9/10 (10%) 
HBcAg  9/10 (10%)  10/10  (0%) 
HBcAg-CS1  0/10 (100%)  1/10  (90%) 
Groups of 10 female  BALB/c  mice were immunized  with PBS, 20/zg 
HBcAg, or 20/~g (HBcAg.CS~) particles emulsified  in CFA and boost- 
ed with the same  doses of antigen  in IFA 2 wk later. 3 mo after  immuni- 
zation, the mice were challenged  with P. berghei by feeding  P. berghei 
ANKA-infeeted  A. stepkensi mosquitoes on their tails. Parasitemia  was 
monitored  by microscopic  examination  of Giemsa-stained  blood  films  daily 
for up to 25 d after challenge. The experiment was repeated a second 
time under identical conditions. 
peptide revealed that the [DP4NPN]2  sequence did not con- 
tain a T cell recognition site relevant for these three strains, 
which explains the inability of HBcAg-CS1 hybrid particles 
to prime CS-specific T  cells. In contrast, the [NANP]n se- 
quence of P. fakiparum  does represent a T  cell recognition 
site in H-2  b haplotype-bearing strains (41, 42).  Immuniza- 
tion of B10(H-2 b) mice with peptide [NANP]4 confirmed 
T  cell recognition of this sequence  by B10 mice, and note 
that [NANP]g-primed T cells were also recalled by HBcAg- 
CS2 particles  in vitro. In the reciprocal  experiment, priming 
with  HBcAg-CS2  hybrid  particles  elicited  HBcAg  and 
[NANP]4-specific  T  cell  proliferative responses  (Table 5). 
This result demonstrates that it is possible to insert a func- 
tional pathogen-derived T cell site between residues 75 and 
81 of HBcAg. This expands the usefulness  of HBcAg as a 
carrier vehicle to include both T and B cell recognition sites, 
and will allow the inclusion of additional malaria-specific Th 
sites which should alleviate the problem of MHC-restricted, 
CS-specific T cell recognition (44). To better understand posi- 
tional effects on the priming of insert-specific T cells, future 
experiments  will  include  the  insertion  of  [NANP]4  at 
different locations within HBcAg. 
Protection Against Malaria.  To study the protective efficacy 
of hybrid HBcAg-CS particles, we immunized BALB/c mice 
with HBcAg, CFA, or HBcAg-CS1 particles and challenged 
them by feeding P. berghei-infected  mosquitoes on their tails. 
This route of challenge was chosen as it represents  a model 
that closely mimics the natural route of malaria transmis- 
sion. 90- 100% of the control BALB/c mice immunized with 
HBcAg or CFA developed parasitemia within 4--6 d after chal- 
lenge (Table 6). In contrast, in two independent experiments 
10/10 mice and 9/10 mice were protected against P. berghei 
challenge after immunization with  HBcAg-CS1  particles. 
This demonstrates that the polyclonal, high titer anti-CS an- 
tibodies elicited by immunization with hybrid HBcAg-CS1 
particles are  also protective. Protection is clearly mediated 
by CS-spedfic antibodies because immunization with HBcAg- 
CSt  particles did not  elicit  CS-specific  T  cells  (Table 5). 
More recently we have constructed hybrid HBcAg-CS parti- 
cles carrying a P. yoelii CS repeat sequence (24) and confirmed 
that BALB/c mice were protected against P. yoelii challenge 
after  immunization with  these  particles  (F.  Sch6del,  D. 
1044  Immunity  to Malaria Elicited by HBcAg-CS Hybrid Particles Peterson, Y. Charoenvit, K. Wirtz, unpublished data). The 
availability of a carrier system which is known to be highly 
immunogenic in humans should now allow us to more con- 
clusively test whether high titer, polyclonal and IgG isotype 
diverse anti-CS antibodies are protective against P.falciparum 
infection. If this proves to be the case, recombinant HBcAg- 
CS particles, possibly incorporating additional plasmodial T 
and B cell sites, may become a component of future malaria 
vaccines. 
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